# Richard D. Gelber

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/richard-d-gelber/

## Facts

| Field | Value |
| --- | --- |
| Citations | 88,215 |
| Field | Breast Cancer Treatment Studies |
| h-index | 133 |
| i10-index | 381 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5040290360 |
| ORCID iD | https://orcid.org/0000-0001-8270-8712 |
| Works | 590 |

## Researcher papers

Showing 12 of 13.

- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment](https://scholariq.org/papers/reduction-of-maternal-infant-transmission-of-human-immunodeficiency-virus-type-1/)
- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus 1 with Zidovudine Treatment](https://scholariq.org/papers/reduction-of-maternal-infant-transmission-of-human-immunodeficiency-virus-1-with/)
- [Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer](https://scholariq.org/papers/adjuvant-olaparib-for-patients-with-i-brca1-i-or-i-brca2-i-mutated-breast-cancer/)
- [2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial](https://scholariq.org/papers/2-year-follow-up-of-trastuzumab-after-adjuvant-chemotherapy-in-her2-positive/)
- [Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials](https://scholariq.org/papers/long-term-outcomes-for-neoadjuvant-versus-adjuvant-chemotherapy-in-early-breast/)
- [Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis](https://scholariq.org/papers/cancer-immunotherapy-efficacy-and-patients-sex-a-systematic-review-and-meta/)
- [Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant](https://scholariq.org/papers/maternal-viral-load-zidovudine-treatment-and-the-risk-of-transmission-of-human/)
- [Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial](https://scholariq.org/papers/pembrolizumab-plus-trastuzumab-in-trastuzumab-resistant-advanced-her2-positive/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)
- [Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis](https://scholariq.org/papers/sex-based-heterogeneity-in-response-to-lung-cancer-immunotherapy-a-systematic/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.